Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 2/20 | 0.34 |
| ▸ | FNTB | P49356 | 2/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CTSA | P10619 | 2/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466250 | 0.85 | CYP11B2 (0.44) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL14562264 | 0.81 | CYP11B2 (0.40) | CYP11B2CYP11B1FNTAFNTB | |
| SCHEMBL17894240 | 0.81 | CYP11B2 (0.38) | CYP11B2CYP11B1FNTAFNTBKDM4D | |
| SCHEMBL3578566 | 0.78 | CYP11B1 (0.41) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL3465562 | 0.78 | CYP11B2 (0.41) | CYP11B2CYP11B1KDM4DIDO1ALPL | |
| SCHEMBL13160967 | 0.76 | MAPK1 (0.41) | CYP11B2CYP11B1LMNA | |
| SCHEMBL3465790 | 0.76 | CYP11B2 (0.38) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL3465242 | 0.76 | CYP11B1 (0.33) | CYP11B2CYP11B1CTSALMNA | |
| SCHEMBL3568025 | 0.75 | HTT (0.50) | CYP11B2CYP11B1FNTAFNTBPGGT1B | |
| SCHEMBL3463864 | 0.74 | FNTA (0.47) | CYP11B2CYP11B1FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | PAPILLON JULIEN | 2010-09-23 | — | — | US | disclosed |
| EP-2029604-A2 | ALDOSTERONE SYNTHASE AND/OR 11BETA-HYDROXYLASE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007139992-A2 | ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240641-A1 | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors | HSD11B1, HSD11B2, CYP11B1 | CYP11B2 4/4885CYP11B1 3/4885FNTA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.